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Structure of UDP-N-acetylglucosamine enolpyruvyl transferase,
an enzyme essential for the synthesis of bacterial
peptidoglycan, complexed with substrate UDP-N-
acetylglucosamine and the drug fosfomycin
Tadeusz Skarzynski*, Anil Mistry†, Alan Wonacott, Susan E Hutchinson, 
Valerie A Kelly and Kenneth Duncan
Background:  UDP-N-acetylglucosamine enolpyruvyl transferase (MurA),
catalyses the first committed step of bacterial cell wall biosynthesis and is a
target for the antibiotic fosfomycin. The only other known enolpyruvyl transferase
is 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase, an enzyme involved in
the shikimic acid pathway and the target for the herbicide glyphosate. Inhibitors
of enolypyruvyl transferases are of biotechnological interest as MurA and EPSP
synthase are found exclusively in plants and microbes.
Results:  The crystal structure of Escherichia coli MurA complexed with UDP-
N-acetylglucosamine (UDP-GlcNAc) and fosfomycin has been determined at
1.8 Å resolution. The structure consists of two domains with the active site
located between them. The domains have a very similar secondary structure,
and the overall protein architecture is similar to that of EPSP synthase. The
fosfomycin molecule is covalently bound to the cysteine residue Cys115,
whereas UDP-GlcNAc makes several hydrogen-bonding interactions with
residues from both domains.
Conclusions:  The present structure reveals the mode of binding of the natural
substrate UDP-GlcNAc and of the drug fosfomycin, and provides information on
the residues involved in catalysis. These results should aid the design of
inhibitors which would interfere with enzyme-catalyzed reactions in the early
stage of the bacterial cell wall biosynthesis. Furthermore, the crystal structure of
MurA provides a model for predicting active-site residues in EPSP synthase that
may be involved in catalysis and substrate binding.
Introduction
Peptidoglycan is an extensively cross-linked polymer essen-
tial for the integrity of the bacterial cell wall. Many antibi-
otics act by disruption of its biosynthesis and assembly,
several are targeted against the cytoplasmic enzymes that
synthesise the key intermediate UDP-N-acetylmuramyl
pentapeptide [1]. One such drug is fosfomycin (phospho-
nomycin, (1R,2S)-1,2-epoxypropylphosphonic acid) [2,3],
which inactivates the first enzyme in this pathway, UDP-
N-acetylglucosamine enolpyruvyl transferase (MurA; E.C.
2.5.1.7, alternative name UDP-N-acetylglucosamine 1-car-
boxyvinyltransferase). The emergence of bacterial strains
resistant to this and to other antibiotics has focused atten-
tion on the need to constantly improve our armament of
antibacterial agents. Detailed study of the reaction mecha-
nisms of several enzymes in the UDP-N-acetylmuramyl
pentapeptide pathway, including MurA, has provided
strategies for the rational design of novel inhibitors, a
process aided by the availability of crystal structures of three
enzymes, UDP-N-acetylenolpyruvyl-glucosamine reductase
[4], D-Alanine:D-Alanine ligase [5] and UDP-N-acetylmura-
mate-L-alanine ligase [6].
The Enterobacter cloacae [7] and Escherichia coli [8] murA
genes have been cloned, sequenced, and coupled to pow-
erful expression systems in order to overproduce large
amounts of the protein in E. coli. In each case, MurA activ-
ity was shown to reside on a single monomeric polypep-
tide chain corresponding to the molecular mass predicted
from the gene sequence. Homologous genes have been
identified in a diverse range of bacterial species, including
Mycobacterium tuberculosis ([9]; KE Kempsell and KD,
unpublished data), Mycobacterium leprae [10], Haemophilus
influenzae [11], Bacillus subtilis [12] and Acinetobacter cal-
coaceticus [13].
There are only two known enolpyruvyl transferases, MurA
and 5-enolpyruvyl-shikimate-3-phosphate (EPSP) synthase,
an enzyme in the shikimic acid pathway leading to the 
precursor of aromatic compounds in plants and microbes,
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chorismic acid. MurA and EPSP synthase share low-level
amino acid sequence similarity (about 20% identity for
enzymes from E. coli [8,14]), but greater similarity at the
structural level was suggested by the presence of a repeating
motif at similar positions in both sequences [8]. The crystal
structure of a substrate-free form of EPSP synthase has been
determined at 2.5Å [15], revealing a distinctive two-domain
structure. However, it does not provide information on the
residues that may be involved in substrate binding and
catalysis. The reaction catalyzed by MurA (Fig. 1a) proceeds
via an addition–elimination mechanism [16], analogous to
that catalyzed by EPSP synthase [17–19]. A noncovalently-
bound tetrahedral ketal intermediate is formed by direct
attack of the 3′-OH of UDP-N-acetylglucosamine (UDP-
GlcNAc) on the C-2 position of phosphoenolpyruvate
(PEP), inorganic phosphate is then eliminated to form 
the product, UDP-N-acetylenolpyruvylglucosamine. Puri-
fied MurA from E. coli and E. cloacae has a molecule of PEP
bound to Cys115 which suggests that the mechanism pro-
ceeds via a phospholactyl enzyme intermediate [20–22].
However, by analysing the E. coli MurA with a Cys115→
Asp115 mutation, it was concluded that covalently bound
PEP is not essential for catalysis [23]. In addition, there is no
evidence for cysteine involvement in the EPSP synthase
mechanism. Each enzyme is exquisitely sensitive to differ-
ent inhibitors: MurA to the antibiotic fosfomycin, which
binds covalently via a thioether bond to Cys115 [3,24]
(Fig. 1b); and EPSP synthase to the herbicide glyphosate
(N-(phosphonomethyl)glycine) [25].
We have determined the three-dimensional structure of
E. coli MurA complexed with UDP-GlcNAc and fos-
fomycin, at 1.8Å resolution. This report describes the struc-
ture, compares it with that of EPSP synthase, and presents
details of protein–substrate interactions.
Results and discussion
Structure determination and refinement
The structure of MurA complexed with UDP-GlcNAc and
fosfomycin was solved by multiple isomorphous replace-
ment (MIR) at 3.2Å resolution and refined at 1.8Å resolu-
tion. Crystals, grown from tert-butanol solutions, were very
unstable at room temperature, and X-ray data collection
was only possible using flash-frozen crystals maintained 
at 100K. A search for heavy-atom derivatives yielded 
three useful derivatives: chloro (2,2′:6′2′′-terpyridine) plat-
inum (II), potassium hexachloroplatinate and potassium
tetrachloroplatinate. Diffraction data for the derivatives
extended to 3.0Å, but only produced useful phasing infor-
mation to about 3.2 Å (Table 1), which resulted in elec-
tron-density maps that were difficult to interpret. Several
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Figure 1
(a) The enolpyruvyl transfer reaction catalyzed by MurA. (b) The
reaction between fosfomycin and Cys115 of MurA, which results in
inactivation of the enzyme.
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Table 1
Crystallographic data.
Data set
Native 1 Native 2 TP10 TP25 PTCL PT04
Resolution (Å) 2.7 1.8 2.8 3.0 2.9 2.8
Complete (%) 95 95 98 98 92 93
Rmerge* 0.105 0.080 0.098 0.113 0.100 0.081
MIR phasing
Riso† 0.300 0.146 0.202 0.164
No. of sites 4 2 1 1
Resolution cut-off (Å) 3.2 3.2 3.2 4.0
Rcullis‡ (centric data) 0.70 0.82 0.88 0.83
Phasing power 1.37 0.91 0.79 0.86
Mean figure of merit = 0.47. Heavy-atom derivatives: TP10: chloro
(2,2′:6′2′′-terpyridine) platinum (II), saturated solution; TP25: chloro
(2,2′:6′2′′-terpyridine) platinum (II), 25 % saturated; PTCL: K2PtCl6,
saturated; PT04: K2PtCl4, 10 mM. *Rmerge = Σhkl Σi | I – < I > | / Σhkl Σi I.
†Riso =Σhkl | (FPH –Fp | /Σhkl FP.
‡Rcullis =Σhkl ||FPH ±FP |–FH(calc) | /Σhkl |FPH ±FP |.
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Figure 2
The mainchain fold of enolpyruvyl
transferases. (a) A schematic representation
of the MurA structure, showing the overall
protein architecture, with the ball-and-stick
model representing UDP-GlcNAc and
fosfomycin molecules bound in the active site.
(b) Stereo representation of the a-carbon
backbone of MurA with every 20th residue
labelled. Thick lines correspond to the
conserved motif Leu-X-X-Leu-Gly-Ala-polar-
hydrophobic-polar (see text). The molecule is
rotated anticlockwise by 90° relative to (a).
(c) A ribbon representation of EPSP synthase
based on the Brookhaven Protein Data Bank
entry 1EPS. In (a) and (c) a-helical regions are
coloured in red. The figure was generated
using the programs MOLSCRIPT [38] and
RASTER3D [39,40].
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density modification, phase extension and model rebuild-
ing rounds were performed, resulting in the complete
determination of the protein structure with the exception
of the C-terminal residue Glu419, which cannot be seen in
the electron-density map. A difference electron-density
map computed after initial refinement of the atomic coor-
dinates for the protein clearly showed an outline of the
UDP-GlcNAc and fosfomycin molecules in the active site.
High-resolution X-ray data collected to 1.8 Å resolution
using synchrotron radiation were subsequently used in 
the refinement of the structure. The refined structure
includes 418 residues, UDP-GlcNAc and fosfomycin, and
422 water molecules. The final crystallographic R factor is
0.185 for all data in the resolution range of 6.0 and 1.8Å.
Overall structure
MurA has two globular domains connected by a double-
stranded linker (Fig. 2a). In this report, the domain contain-
ing the catalytic Cys115 (residues 22–229) will be termed
the catalytic domain, and the other domain (residues 1–21
and 230–419) will be called the C-terminal domain. The
mainchain fold of each domain is very similar, with three
parallel internal helices surrounded by three helices and
three four-stranded b-sheets exposed to solvent. There 
is an approximate threefold symmetry which relates sec-
ondary structure elements within each of the domains.
Marquardt et al. [8] suggested that the MurA sequence may
be divided into six units of approximately 70 residues, each
containing a conserved motif, Leu-X-X-Leu-Gly-Ala-polar-
hydrophobic-polar. In the crystal structure of MurA, this
conserved motif corresponds to the arrangement involving
the C-terminal end of the exposed helix, a connecting loop
and the N-terminal end of the first strand in the adjacent
b sheet (Fig. 2b).
Comparison of the MurA and EPSP synthase structures
The overall protein fold is very similar to that of EPSP syn-
thase [15] (Fig. 2c), although several loops connecting the
secondary structure elements differ in length and confor-
mation. The relative orientation of the domains differs sig-
nificantly; in EPSP synthase, the enzyme is in an ‘open’
conformation with an empty active site, whereas MurA is
in a ‘closed’ conformation, with the two domains envelop-
ing substrate and inhibitor. In MurA, the loop 111–121 has
an extended conformation, creating a ‘lid’ over the catalytic
pocket, whereas the corresponding stretch of the EPSP
synthase polypeptide chain forms a short helix. In MurA,
there are glycine residues at both ends of the loop 111–121,
and it is very likely that the conformation of this solvent-
exposed part of the molecule is different in an open form.
Several other loops near the active-site pocket vary in
length and conformation in the two enzymes (Fig. 2).
The MurA and EPSP synthase structures also differ in the
length and relative orientation of individual b strands and
helices. For example, the C-terminal strand in MurA
belongs to the ‘four-b-strand, two-a-helix’ motif, repeated
six times in the structure of the enzyme, while in EPSP
synthase the polypeptide chain ends somewhat earlier,
and the fourth b strand of the motif is missing. Stallings et
al. [15] suggested that the topological symmetry of EPSP
synthase may reflect sixfold gene replication. They also
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Figure 3
A stereo representation of the active site of
MurA with a cross-section through the
molecular surface of the enzyme (white dots)
showing surface complementarity between
the ligands and the protein (stick
representation). UDP-GlcNAc and fosfomycin
are represented as van der Waals spheres.
Atoms are depicted in standard colours. Only
residues mentioned in the text are shown,
along with water molecules (represented as
red crosses) trapped in the catalytic pocket.
Figure was produced with the program
QUANTA (Molecular Simulations Inc.).
noted that the arrangement of the 12 helices in EPSP syn-
thase, with their N termini pointing towards the active
site, may favour the binding of negatively charged ligands.
The similar arrangement of the helices in MurA suggests
that it may have a similar role in binding of the negatively-
charged substrates UDP-GlcNAc and PEP.
The catalytic site
The catalytic site is situated in a deep cavity between the
two domains (Fig. 3). There are 10 direct interdomain hydro-
gen bonds involving residues distributed around the catalytic
pocket. These include four hydrogen bonds between loops
46–49 and 396–400 (including the salt bridge Asp49–Arg397),
three hydrogen bonds between the loops 116–119 and 329-
330, a hydrogen bond between Glu188 and His299, and two
hydrogen bonds (a salt bridge) between Glu190 and Arg232
at the bottom of the active-site cavity. There are no large
hydrophobic patches buried between the domains and only 
a few hydrophobic interactions between single residues can
be found in the interface (e.g. Ile117–Phe328 and Val161–
Pro298). The interdomain interactions stabilise the closed
conformation of the enzyme, but may also play a more spe-
cific role in catalysis, by controlling access to the active site at
different stages of the reaction. For example, the salt bridge
between Asp49 and Arg 397 (both residues conserved in all
known MurA sequences) is positioned between the active
site and the bulk solvent, with the arginine contributing to
the phosphate-binding site (see further below).
Interactions between MurA and UDP-GlcNAc
The uridinyl ring of UDP-GlcNAc is sandwiched between
two hydrophobic surfaces created by Arg120 and Pro121
on one face and Leu124 on the other, ensuring a good fit
of the molecular surfaces (Fig. 3). These interactions, com-
bined with the hydrogen bonds involving uridinyl base
atoms N1 and O1, provide good binding specificity for this
base. There is less surface complementarity between the
N-acetylglucosamine moiety and the protein. The sugar
rests against one side of the active site pocket and interacts
with a number of water molecules trapped there; it makes
three hydrogen bonds with the protein involving Asn23
(one bond) and Asp305 (two bonds) from the C-terminal
domain (Fig. 4). The principal substrate-binding interac-
tions involve oxygen atoms from the pyrophosphate bridge
of UDP-GlcNAc, which make hydrogen bonds to two
mainchain nitrogen atoms of Val163 and Gly164, a hydro-
gen bond with the hydroxyl oxygen of Ser162, and two
hydrogen bonds with arginine residues Arg91 and Arg120
(Fig. 4).
There are several pools of buried solvent molecules.
Between UDP-GlcNAc and the C-terminal domain of the
enzyme, a cluster of three water molecules fills a cavity at
the bottom of the active site. A chain of water molecules
creates a narrow channel in the C-terminal domain between
the ribose ring of UDP-GlcNAc and the exposed surface of
the protein, close to helix 260–269 and loop 298–304. Water
molecules fill small cavities near the N-acetylglucosamine
moiety. There is a distinctive cleft on the surface of the cat-
alytic domain, surrounding most of the substrate-binding
site, whose charge distribution is complementary to that of
the substrate (Fig. 5). The shape complementarity, and the
specific protein–ligand interactions between UDP-GlcNAc
and the catalytic domain, indicate this cleft may be the
likely site of initial substrate recognition and binding to the
open form of the protein.
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Figure 4
A schematic diagram of hydrogen bonds made by (a) UDP-GlcNAc
and (b) fosfomycin with residues of MurA (thin lines). Residues of both
ligands are shown as thick lines. Hydrogen bonds are denoted as
dashed lines.
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Interactions between MurA and fosfomycin
Fosfomycin is tightly packed between the enzyme and
UDP-GlcNAc (Figs 3,5), making hydrogen bonds with
several different segments of the polypeptide chain (Fig.
4b). There are also hydrogen bonds between the fosfomycin
hydroxyl group and the C-3 hydroxyl of the UDP-GlcNAc
sugar ring, and between one of its phosphonate oxygen
atoms and the amide nitrogen of UDP-GlcNAc (Fig. 4a).
Three positively charged residues of MurA (Lys22, Arg120
and Arg397) surround the phosphonate group, providing
strong electrostatic interactions and making five hydrogen
bonds with it. Lys22 and Arg120 are conserved in all known
MurA and EPSP synthase sequences, whereas there is a
lysine residue in EPSP synthase corresponding to MurA
Arg397. The shape of this phosphonate-binding site and 
the geometry of specific interactions suggest that the phos-
phate group of the natural substrate, PEP, also binds to this
site. The arrangement of the arginine residues around the
phosphate site is different from the geometry of interactions
suggested by Li and co-workers [26]. In their time-resolved
solid state NMR spectroscopy study of MurA from E. cloacae
they predicted side-by-side interactions of a non-specific
arginine with PEP, involving the internal nitrogen atom of
the guanidino group.
Near the thioether bond with Cys115, there is a pocket
between the fosfomycin carbon atom C-3 and two arginines
(Arg331 and Arg371) that contains two water molecules.
The arrangement of the arginine sidechains strongly sug-
gests this pocket to be a binding site for the carboxy-
late group of PEP, particularly because the arginines are 
conserved in structure-based alignment of other MurA and
EPSP synthase sequences. The fosfomycin-MurA struc-
ture, therefore, provides a good starting point for modelling
PEP in its covalently bound form and for modelling other
enzyme-bound intermediates of the reaction mechanism.
Conformational change upon binding substrate
Two observations suggest that MurA undergoes a confor-
mational change during catalysis. Firstly, in the present
structure, only the uridinyl and ribose rings of UDP-
GlcNAc are exposed to solvent, so the domains must move
apart for substrates to enter and products to leave. Sec-
ondly, the EPSP synthase structure suggests an alternative
conformation for apo-MurA. From modelling studies of the
MurA structure in its open conformation, we predict that,
in addition to changes in the relative disposition of the two
domains, the conformation of the loop 111–121 will be
altered upon substrate-binding. We propose that the active
site is created by induced fit following initial recognition
and binding of UDP-GlcNAc, which in turn triggers a con-
formational change of the 111–121 loop, bringing Cys115
and PEP into place for reaction. This prediction is sup-
ported by the observation that time-dependent inactivation
of MurA by fosfomycin is greatly accelerated by UDP-
GlcNAc and also by unreactive 3′-deoxy-UDP-GlcNAc
[24], implying that the binding of each influences a confor-
mation change which facilitates the reaction of Cys115 with
fosfomycin. The model also predicts that, in the open con-
formation, the contribution of Arg397 to the phosphate-
binding site and to the salt-bridge with Asp49 would no
longer be possible. This salt bridge is positioned between
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Figure 5
A stereo representation of the cavity in the
catalytic domain of MurA surrounding the UDP-
GlcNAc and fosfomycin molecules
(represented by stick models). Protein atoms
are shown as van der Waals spheres. Nitrogen
atoms are coloured in blue, oxygen atoms in
red, the sulphur atom of Cys115 in yellow. The
C-terminal domain and water molecules are not
shown. Figure was produced with the program
QUANTA (Molecular Simulations Inc.).
the active site and the bulk solvent. Disruption resulting
from some rearrangement of charge distribution during the
final stage of the reaction would provide an opening to the
active site, thereby allowing inorganic phosphate to leave
and a molecule of PEP to gain access. Structure-based
sequence alignment suggests that Asp49 and Lys411 would
form a similar salt bridge in EPSP synthase.
Catalytic residues
The involvement of Cys115 in catalysis was established 
by site-directed mutagenesis studies: the substitution of
this residue with serine or alanine results in an inactive
enzyme [21,27]. However, Cys115 is replaced by an aspar-
tate residue in the sequence of a gene from M. tuberculosis
with 45% identity to the E. coli MurA gene (KE Kempsell
and KD, unpublished data). This observation prompted a
recent study into the consequence of aspartate substitution
in E. coli MurA, which revealed that the mutated enzyme is
highly active but resistant to inactivation by fosfomycin
[23]. The results of this study imply that the cysteine or
aspartate residue at position 115 performs the role of a
general acid in the protonation of C-3 of PEP during the
reaction. The crystal structure confirms that Cys115 is suit-
ably positioned to play this role (Figs 3,5). The properties of
this cysteine may be modulated by the relative disposition
of certain charged sidechains in the catalytic site and by
their movement during various stages of the reaction. For
instance, the guanidinium moieties of Arg120 and Arg397
(conserved in all sequences) are close to Cys115, being 4.4Å
and 3.4Å from the sulphur atom, respectively. Structure-
based sequence alignment suggests that Glu118 in EPSP
synthase, which corresponds to Gly114 in MurA, may have
the catalytic role of Cys115. This hypothesis is supported by
the observation that replacement of Cys115 in MurA with
glutamate also yields an active enzyme, albeit with 1% of
the activity of the aspartate mutant [23]. Two charged
residues close to Glu118 in EPSP synthase (Lys122 and
Glu123) could be involved in modifying the acid-base prop-
erties of the glutamate. 
The role of the covalently bound PEP in MurA catalysis is
unclear, as recent data prove that it is not required for catal-
ysis and that non-covalently bound PEP is the species that
reacts with UDP-GlcNAc [19,23]. Modelling suggests that
the catalytic Cys115 is likely to be exposed to solvent in
the open form of the enzyme. One possible function of this
covalent bond may be to protect the cysteine from oxida-
tion and from cross-linking with other cysteine-containing
protein molecules. A thioester group in the human comple-
ment component C-4 has a similar function, keeping the
acyl group ready for activation and protecting the thiol
group from oxidation [28].
A candidate for the role of base in the initial deprotonation
of the UDP-GlcNAc C-3 hydroxyl is Asp305 (Figs 3,4a).
This residue makes two hydrogen bonds with the sugar
ring, including a bond with the C-3 hydroxyl (2.9Å). Rear-
rangements in this region during the formation of the
tetrahedral intermediate may facilitate the conformational
change leading to the release of the products at the final
stage of the reaction. An aspartate residue at the struc-
turally equivalent position 313 is conserved in all known
sequences of EPSP synthase [27].
Biological implications
Antibiotics acting at different stages in the pathway
leading to formation and assembly of bacterial peptidogly-
can have been in clinical use for several decades.
However, the emergence of drug-resistant bacteria has
highlighted the need to continue to develop new classes of
drugs. This has stimulated interest in the essential cyto-
plasmic enzymes that synthesise the key intermediate 
in peptidoglycan synthesis, UDP-N-acetylmuramyl pen-
tapeptide. The first step in this process is the formation 
of UDP-N-acetylenolpyruvylglucosamine from phos-
phoenolpyruvate (PEP) and UDP-N-acetylglucosamine
(UDP-GlcNAc), a reaction catalysed by  UDP-N-acetyl-
glucosamine enolpyruvyl transferase (MurA). Inhibitors
of enolpyruvyl transferases are of potential commercial
interest, because the only two known examples of this
enzyme class, MurA and 5-enolpyruvylshikimate-3-phos-
phate (EPSP) synthase, are found exclusively in plants
and microbes. The discovery of fosfomycin and glypho-
sate, as specific inhibitors of MurA and EPSP synthase,
respectively, has highlighted this potential and also pro-
vided a means to confirm the previously determined cat-
alytic mechanisms of the two enzymes. Interestingly,
although both inhibitors were thought to compete with
PEP, each did not inhibit both enzymes and it was con-
cluded that the reactions were catalysed in different
ways. More recently, gene sequencing and refined bio-
chemical studies have shown that the enzymes and their
mechanism are indeed related, and this is further sup-
ported by close structural similarity.
The structure of MurA complexed with substrate (UDP-
GlcNAc) and inhibitor (fosfomycin), has the same
overall protein fold as EPSP synthase, with two globular
domains and the catalytic site situated in a cavity
between the domains. However, the relative orientation
of the domains is different in the two structures; the sub-
strate-free form of EPSP synthase is in an ‘open’ con-
formation, whereas MurA is in a ‘closed’ conformation.
The substrate and the inhibitor are bound in a deep
active-site cavity interacting with residues from both
domains. Fosfomycin is covalently-bound to the catalytic
cysteine residue and can serve as a model for the cova-
lently-bound form of PEP.
The high-resolution structure of MurA provides a wealth
of information on the residues involved in MurA substrate
binding and catalysis and gives a firm base for detailed
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predictions of corresponding residues in EPSP synthase.
It thus provides a template upon which novel inhibitors of
this important enzyme class may be designed.
Materials and methods
Expression, purification and crystallization
E. coli MurA was isolated from the overproducing strain JLM16, with the
following modifications from the method described previously [8]. After
lysing the cells and centrifuging at low speed to remove cell debris, the
extract was clarified by centrifugation at 100 000 × g for 2h at 4°C, then
dialyzed overnight against 50 mM TRIS.HCl, pH 8.0, 2 mM dithiothreitol.
The ammonium sulphate step was omitted. Following chromatography
of this material on Hi-Load Q Sepharose (Pharmacia), pooled active
fractions were concentrated by ultrafiltration (Amicon PM30 membrane)
to ~50ml and applied to a 2L Superdex G75 (Pharmacia) gel filtration
column (102cm × 5cm). Purified MurA was eluted in 50 mM TRIS.HCl,
pH 8.0, 150mM NaCl, 2mM dithiothreitol. Purity was routinely assessed
by sodium dodecyl sulphate polyacrylamide gel electrophoresis and by
liquid chromatography and mass spectroscopy.
Crystals were grown using the sitting-drop vapour-diffusion method from
a solution of ~10mgml–1 of protein, 2.5mM UDP-GlcNAc and 2.5mM
fosfomycin, mixed with reservoir solution containing 25 % tert-butanol,
100mM CaCl2, 10% glycerol and 100 mM TRIS buffer, pH 8.5. The
enzyme crystallized in space group P321 with one molecule in the asym-
metric unit. The cell dimensions are: a =110.7Å, c=67.6Å.
Data collection and processing
The X-ray data for the native crystals (2.8 Å resolution) and for the
heavy-atom derivatives were collected on an Enraf-Nonius FAST area
detector, mounted on a rotating-anode X-ray generator. The crystals
were harvested from their original drops to a solution containing 40%
tert-butanol, 10 % glycerol, 100 mM CaCl2, 100 mM TRIS buffer, pH 8.5,
and, for heavy-atom soaks, an appropriate heavy-atom compound. The
crystals used for data collection were then briefly soaked in correspond-
ing solutions, with glycerol concentration raised to 20 %, and flash-
frozen at 100 K in a stream of dry nitrogen, using the Cryostream system
(Oxford Cryosystems). Data processing was carried out using the
program MADNES [29] and programs from the CCP4 suite [30]. The
native X-ray data to 1.8 Å resolution were collected from one cryocooled
crystal on station 9.6 at the synchrotron radiation source at Daresbury,
using a MAR-research image plate and processed using MOSFLM [31]. 
Structure determination and refinement
The structure of MurA was solved by the method of multiple isomor-
phous replacement (MIR) using three different platinum derivatives:
chloro (2,2′:6′2′′-terpyridine) platinum (II) (data sets TP10 and TP25),
potassium hexachloroplatinate (PTCL) and potassium tetrachloroplati-
nate (PT04) (Table 1). Atomic coordinates of the platinum atom of the
PTCL derivative were found using the direct methods program SHELX
[32], and refined with the phase refinement program MLPHARE [30].
Single isomorphous replacement phases computed from this derivative
were used to calculate difference Fourier maps that revealed coordi-
nates of the heavy-atom sites for the other derivatives. Several cycles of
phase refinement were performed giving the final overall figure of merit
of 0.47 for data between 20.0–3.2Å for the four derivatives. Data sets
TP10 and TP25 were collected from crystals soaked in the same heavy-
atom compound solution, at different concentrations and for different
lengths of time. As the relative occupancy of the common sites
appeared to be significantly different, we included both data sets in the
phasing, treating them as different derivatives. Binding of the heavy-
atom compounds was examined later by calculating difference maps
phased with the refined protein coordinates. The PTCL binding site was
found to be close to the methionine residue Met366, the PT04 site is
situated near Met1, three of the four TP10 sites are close to external
histidine residues (His155, His285 and His344), and one TP10 binding
site was found in the proximity of the exposed cysteine residue Cys81.
The TP25 (lower concentration of the platinum compound) sites were
close to Cys81 and His155 with the relative levels of electron density
different from the corresponding sites of TP10.
The electron-density map at 3.2 Å resolution calculated using the MIR
phases was noisy but it clearly showed the outline of the protein mol-
ecules in the unit cell and their similarity to the structure of EPSP syn-
thase [15] with the pseudo-symmetrical arrangement of helices within
the molecules. The quality of the map was greatly improved by the
solvent-flattening procedure using the program DM [30], although
several mainchain discontinuities remained, and some regions of the
map were still poorly defined. Initial interpretation of the map was
helped by using the a-carbon co-ordinates of the EPSP synthase struc-
ture. A model of the mainchain fold of MurA, based on fragments of the
a-carbon co-ordinates of EPSP synthase (PDB entry code 1EPS), was
fitted into the solvent-flattened MIR map using the program FRODO
[33], and used to create a molecular mask for subsequent density-
modification and phase combination procedures performed using pro-
grams from the CCP4 suite. This further improved the quality of the
map and enabled interpretation of most of the electron density. Rounds
of model building, density modification, phase combination and phase
extension were performed resulting in fitting the complete polypeptide
chain except for the disordered, C-terminal residue Glu419. The Rfree
indicator [34] was used to monitor the progress of the structure deter-
mination until it reached a value of 0.245 for 1.8 Å resolution data. It
was not used in the final round of the refinement, which was based on
all reflections. Automatic Refinement Program (ARP) [35], used during
final stages of model building, proved invaluable in removing model
bias and allowing correction of several mistakes made in the initial
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Figure 6
The difference electron density corresponding to UDP-GlcNAc and
fosfomycin bound to the active site of MurA. The map is calculated 
at 1.8 Å resolution. Atoms are shown in standard colours. Figure was
produced with the program QUANTA (Molecular Simulations Inc.).
interpretation. For example, an electron-density map resulting from the
ARP procedure showed that a long segment of the polypeptide chain
on the surface of the molecule (residues 320–370) contained amino-
acid segments that were shifted by up to eight residues from their true
positions. Correct positions were indicated by the shape of sidechain
electron density. Difference electron density corresponding to UDP-
GlcNAc and fosfomycin, computed after the initial refinement of the
protein, was very clear, and the atomic co-ordinates of both ligands
were subsequently included in the model (Fig. 6).
The structure was initially refined using the program PROLSQ [36], and
the program X-PLOR [37] was used at later stages. Several rounds of
model rebuilding and structure refinement were performed at increasing
resolution using the 1.8Å data set until convergence was reached, with
the final crystallographic R factor of 0.185 for all 40374 reflections in
the 6.0–1.8Å resolution range. The root mean square (rms) deviations of
bond lengths and angles from stereochemical standards were 0.018 Å
and 2.85° respectively. The final difference electron-density map was
devoid of any features significantly higher than noise level. The model
has been examined using the program PROCHECK [30]. It shows good
geometry (Fig. 7), with 93.6% residues having the f/ψ torsion angles in
the most favoured region of the Ramachandran diagram, 5.8 % in addi-
tional allowed regions, 0.6 % (two residues) in generously allowed
regions, and no residues in disallowed regions of the diagram.
Accession numbers
The atomic coordinates for MurA have been deposited in the Brookhaven
Protein Data Bank with the code number 1UAE.
Note added in proof
The structure of an apo form of MurA from highly homologous Enterobac-
ter cloacae was published recently (Schönbrunn, E., et al., & Mandelkow,
E. (1996). Crystal structure of UDP-N-acetylglucosamine enolpyruvyltrans-
ferase the target of the antibiotic fosfomycin. Structure 4, 1065–1075). It
confirms our hypothesis regarding the conformation changes that take
place during catalysis.
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